Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
复制标题
DOI：
10.1186/s12876-015-0266-6
复制
发表时间：
2015-03-24
影响因子：
2.4
通讯作者：
Zdrazilova-Dubska L
中科院分区：
文献类型：
--
作者：
Bencsikova B;Bortlicek Z;Halamkova J;Ostrizkova L;Kiss I;Melichar B;Pavlik T;Dusek L;Valik D;Vyzula R;Zdrazilova-Dubska L
本回顾性研究的目的是根据一线接受贝伐珠单抗（bev）联合化疗的转移性结直肠癌（mCRC）患者的KRAS状态，分析临床结局和与治疗结局相关的风险因素。我们对1622例mCRC患者进行了观察性研究，这些患者接受了bev联合奥沙利铂或伊立替康化疗，并将治疗结果与KRAS突变状态相关联。主要终点是无进展生存期（PFS）和总生存期（OS）。评价了贝伐单抗的不良事件和风险因素，包括转移部位。40.6%的mCRC病例中存在KRAS突变。野生型KRAS（wtKRAS）与突变型KRAS患者的中位PFS分别为11.5个月与11.4个月。中位OS为30.7 vs 28.4个月（p = 0.312）。KRAS突变患者的肺转移率高于wtKRAS患者（32.0% vs 23.8%; p = 0.001）。我们观察到肝转移性疾病和肝外转移性疾病的临床结局没有差异。KRAS突变不会干扰mCRC患者接受贝伐珠单抗联合化疗一线治疗的临床获益。本文的在线版本（doi：10.1186/s12876-015-0266-6）包含补充材料，可供授权用户使用。
The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients. The online version of this article (doi:10.1186/s12876-015-0266-6) contains supplementary material, which is available to authorized users.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-10-0529
发表时间：
2010-11
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Chan AT;Baba Y;Shima K;Nosho K;Chung DC;Hung KE;Mahmood U;Madden K;Poss K;Ranieri A;Shue D;Kucherlapati R;Fuchs CS;Ogino S
通讯作者：
Ogino S
影响因子：
3.7
作者：
Díaz-Rubio E;Gómez-España A;Massutí B;Sastre J;Reboredo M;Manzano JL;Rivera F;Safont MJ;Montagut C;González E;Benavides M;Marcuello E;Cervantes A;Martínez de Prado P;Fernández-Martos C;Arrivi A;Bando I;Aranda E;Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
通讯作者：
Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
影响因子：
8.8
作者：
Basso, M.;Strippoli, A.;Barone, C.
通讯作者：
Barone, C.
影响因子：
45.3
作者：
Giantonio, Bruce J.;Catalano, Paul J.;Benson, Al B., III
通讯作者：
Benson, Al B., III
影响因子：
11.5
作者：
Tie, Jeanne;Lipton, Lara;Sieber, Oliver M.
通讯作者：
Sieber, Oliver M.